Project Grant R01CA289294
Award Date
5/1/25
Completion Date
4/30/30
Dollars Obligated
$671K
Federal Agency
National Cancer Institute
Federal Grant Program
93.394
Assistance Type
Project Grant
Place of Performance
Illinois, USA
Similar Awards
This $592,866 Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) aims to develop ingestible nanosensors that can detect early-stage colorectal cancer through a non-invasive, breath-based approach. The nanosensors are engineered to sense intestinal enzyme activity related to tumor development and produce amplified reporter signals in the breath that can be detected by mass spectrometry. This novel platform technology is being tested in...
This Cooperative Agreement award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $639,780.00 to The Leland Stanford Junior University to develop a novel approach for single-molecule methylation analysis of cell-free DNA (cfDNA) to detect early-stage colorectal cancer. The project aims to (1) characterize the early-stage colorectal cancer cfDNA methylome landscape, and (2) develop a machine learning model for early detection of colorectal...
The National Cancer Institute (NCI) awarded a $400,000 Project Grant under CFDA 93.394 "Cancer Detection and Diagnosis Research" to Electronic Biosciences, Inc., a small biotechnology company in San Diego, CA. The funding will support the development of a novel nanopore-based sequencing approach to accurately characterize repetitive DNA sequences, which are challenging to analyze using current sequencing-by-synthesis technology. This capability will enable improved cancer...
This National Cancer Institute Project Grant under CFDA 93.394 "Cancer Detection and Diagnosis Research" will develop and validate a multi-stage, multi-modal biomarker to predict the risk of progression from oral premalignant lesions (OPLs) to oral cavity squamous cell carcinoma (OSCC). The project, titled "PROSPECT: Premalignant Oral Lesions Pathology and Epigenetic Risk Prediction Tool," will use a combination of cytology, histology, and epigenomics to create a risk...
This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) to The General Hospital Corporation (d/b/a Massachusetts General Hospital) provides $1,471,777 to develop and clinically validate new optical coherence tomography (OCT) systems and probes for improved colorectal cancer screening. The key products and services to be delivered include: Creating an OCT system and two distinct OCT imaging probes optimized for adenoma screening. One...
The National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) awarded a $224,099 Project Grant to the University of California, San Diego (UCSD) to develop a targeted colorectal cancer (CRC) screening strategy for adults ages 45-49. The key objectives are to: 1) characterize the acceptability of CRC screening in this age group and identify factors influencing screening uptake, and 2) conduct a randomized controlled trial to evaluate the comparative effectiveness of an active outreach...
This Project Grant award from the National Cancer Institute (CFDA 93.396 Cancer Biology Research) provides $230,010 to the University of Chicago to develop and apply a novel epigenome sequencing platform called GLIMP-SEQ. The platform will enable enrichment and high-fidelity profiling of 5-methylcytosine (5mC) in degraded clinical samples, such as formalin-fixed, paraffin-embedded (FFPE) cancer tissues and cell-free DNA (cfDNA) from colorectal cancer patients. GLIMP-SEQ leverages enzymatic...
The National Cancer Institute (NCI), through the Cancer Detection and Diagnosis Research program (CFDA 93.394), awarded a $400,000 Project Grant to Argosmd, Inc. to develop a low-cost, non-invasive Mini-Reflectance Confocal Microscope (Mini-RCM) device for aiding skin cancer diagnosis and treatment. The goal is to create a portable, fast-imaging Mini-RCM that can enable rapid examination of multiple skin lesions, addressing limitations of the current high-cost, cart-based reflectance confocal...
The National Cancer Institute (NCI) awarded a $398,738 Project Grant under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to Pre-Cancer Diagnosis, LLC to develop a highly sensitive DNA hypermethylation-based diagnostic kit to identify Barrett's Esophagus (BE) patients at high risk of progressing to esophageal adenocarcinoma (EAC). The key objectives are to: 1) validate the hypermethylation genes and develop a methylation diagnostic kit to differentiate high-risk BE patients...
The National Cancer Institute (NCI) awarded a $962,560 Project Grant under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to Basic Health International Inc., a non-profit organization in Pittsburgh, Pennsylvania. The funding will be used to modify and clinically validate the IRISTM device, a handheld thermal ablation device and digital colposcope designed for cervical cancer screening and treatment in low- and middle-income countries (LMICs). Specifically, the project aims to:...